Follicular Lymphoma Market Treatment, Analysis, Outlook and Pipeline Review, H1 2016
Transcription
Follicular Lymphoma Market Analysis and Outlook, Overview and Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Follicular Lymphoma - Pipeline Review, H1 2016', provides an overview of the Follicular Lymphoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Follicular Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Follicular Lymphoma and features dormant and discontinued projects. For More Information, Visit @ http://www.radiantinsights.com/research/follicular-lymphoma-pipeline-reviewh1-2016 Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Follicular Lymphoma - The report reviews pipeline therapeutics for Follicular Lymphoma by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Follicular Lymphoma therapeutics and enlists all their major and minor projects - The report assesses Follicular Lymphoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Follicular Lymphoma Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Follicular Lymphoma - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Follicular Lymphoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Request Sample Copy of This Report @ http://www.radiantinsights.com/research/follicular-lymphomapipeline-review-h1-2016/request-sample Table of Contents Table of Contents 2 Introduction 6 Follicular Lymphoma Overview 7 Therapeutics Development 8 Follicular Lymphoma - Therapeutics under Development by Companies 10 Follicular Lymphoma - Therapeutics under Investigation by Universities/Institutes 14 Follicular Lymphoma - Pipeline Products Glance 15 Follicular Lymphoma - Products under Development by Companies 18 Follicular Lymphoma - Products under Investigation by Universities/Institutes 24 Follicular Lymphoma - Companies Involved in Therapeutics Development 25 Follicular Lymphoma - Therapeutics Assessment 76 Drug Profiles 91 Follicular Lymphoma - Recent Pipeline Updates 303 Follicular Lymphoma - Dormant Projects 520 Follicular Lymphoma - Discontinued Products 523 Follicular Lymphoma - Product Development Milestones 524 Appendix 532 For More Information, Visit @ http://www.radiantinsights.com/research/follicular-lymphoma-pipeline-reviewh1-2016 About Us: Radiant Insights Inc. is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions. Contact Details: Michelle Thoras Corporate Sales Specialist, USA Radiant Insights, Inc 28 2nd Street, Suite 3036 San Francisco, CA 94105 United States Phone: 1-415-349-0054 Toll Free: 1-888-202-9519 Website: http://www.radiantinsights.com/ Email: sales@radiantinsights.com Visit our Blog: http://chemicalsandmaterialsri.blogspot.com
Similar documents
Global Follicular Lymphoma Industry Size, Segmentation, Demand Forecast Report Up To 2015: Radiant Insights, Inc
Follicular Lymphoma - Pipeline Review, H2 2015', provides an overview of the Follicular Lymphoma's therapeutic pipeline. Read More @ http://www.radiantinsights.com/research/follicular-lymphoma-pipeline-review-h2-2015
More informationClinical Cancer Research Highlights of This Issue 5145 SPECIAL FEATURES CCR Translations
More information
Global Diffuse Large B-Cell Lymphoma Market Size, Growth, Trends & Forecast Report To 2015: Radiant Insights, Inc
'Diffuse Large B-Cell Lymphoma - Pipeline Review, H2 2015', provides an overview of the Diffuse Large B-Cell Lymphoma's therapeutic pipeline. Read More @ http://www.radiantinsights.com/research/diffuse-large-b-cell-lymphoma-pipeline-review-h2-2015
More informationHodgkin Lymphoma Market 10 Year Epidemiology Forecasts in 7 Major Markets
The Hodgkin’s lymphoma treatment market is set to increase more than fourfold from $316 million in 2014 to $1.4 billion by 2024, representing a Compound Annual Growth Rate (CAGR) of 16%. Hodgkin’s lymphoma (HL), or Hodgkin’s disease, is a malignancy which involves the lymph nodes and the lymphatic system. HL is a relatively rare type of cancer, accounting for 12% of all lymphomas and 0.6% of all new cancer cases, but overall prognosis is very good.
More informationLatest Report - Global B-Cell Non-Hodgkin Lymphoma Industry Size, Growth Trends, 2015: Radiant Insights, Inc
'B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H2 2015', provides an overview of the B-Cell Non-Hodgkin Lymphoma's therapeutic pipeline.. Visit Us @ http://www.radiantinsights.com/research/b-cell-non-hodgkin-lymphoma-pipeline-review-h2-2015
More information